Immunocore Holdings plc (IMCR): Cash & Equivalents
$467.71M
As of 2025-12-31
$484.92M
As of 2026-06-30
+5.1%
3-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $467.71M | +2.6% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $455.73M | +3.0% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $442.63M | +10.0% | 2025-02-26, Balance as of period end |
| 2022-12-31 | $402.47M | n/a | 2024-02-28, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $467.71M | +2.6% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $496.30M | +43.9% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $183.05M | -19.1% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | $183.64M | +93.7% |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $87.63M | -15.0% |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $70.50M | +47.1% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $163.08M | +41.0% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
Compare IMCR, KRYS, TWST, TARS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗